Company focusing on key pipeline programs NKTR-358, NKTR-255 and core research programs Cost restructuring plan results in cash runway into the first half of 2025 Analyst and investor conference call today at 5:00 PM ET (2:00 PM PT) SAN FRANCISCO, April 25, 2022 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) today announced a new strategic plan focused on prioritizing key research and development efforts that will be most impactful to the company’s future, including its NKTR-358, NKTR-255 and several core research programs. In connection with this new strategic plan, Nektar also announced a cost restructuring plan aimed at ensuring Nektar […]
Nektar Therapeutics Announces Strategic Reorganization Plan and Corporate Outlook
RELATED ARTICLES
